Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx Inks Exclusive Licensing Deal with Claremont BioSolutions

NEW YORK (GenomeWeb) – IncellDx today announced a worldwide exclusive licensing and supply agreement to couple the firm's reagents with Claremont BioSolutions' enzyme-free tissue homogenization technology.

The combination sample prep system will be called IncellPrep Liquid Biopsy and will prepare cell suspensions from either fresh or FFPE tissues for molecular diagnostics by flow or image cytometry.

The combination of technologies "circumvents the problems of using different technologies for different specimen types by creating a 'Universal Specimen.' This will allow IncellDx to compete in the histology and immunohistochemistry space with our single-cell multiplex technology in cancer and infectious disease," IncellDx CEO Bruce Patterson said in a statement.

Upland, Calif.-based Claremont BioSolutions specializes in miniature, disposable devices in the sample prep space. Menlo Park, Calif.-based IncellDx combines molecular diagnostics with high-throughput cellular analysis.

Financial and other terms of the deal were not disclosed.